Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172163 | 0.82 | MAOB (0.61) | MAOBMAOAIDO1F2AR | |
| SCHEMBL4639733 | 0.82 | MAOB (0.61) | MAOBMAOAIDO1F2AR | |
| SCHEMBL5090324 | 0.80 | MAOB (0.59) | MAOBIDO1AR | |
| SCHEMBL5095783 | 0.79 | OPRM1 (0.47) | MAOBLNPEPSLC6A4FFAR1FFAR4 | |
| SCHEMBL4325707 | 0.78 | MAOB (0.56) | MAOBMAOAIDO1F2SPHK2 | |
| SCHEMBL12423202 | 0.78 | MAOB (0.68) | MAOBMAOAIDO1ARSPHK2 | |
| SCHEMBL15613736 | 0.77 | MAOB (0.58) | MAOBMAOAIDO1F2SPHK2 | |
| SCHEMBL6998451 | 0.77 | MAOB (0.55) | MAOBMAOAIDO1F2SPHK2 | |
| SCHEMBL5087354 | 0.76 | MAOB (0.53) | MAOBFFAR1ALOX5ALOX5AP | |
| SCHEMBL6331479 | 0.76 | MAOB (0.66) | MAOBMAOAIDO1F2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722929-B2 | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2014-05-13 | — | — | US | disclosed |
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | JPMORGAN CHASE BANK, N.A. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNJ2, KCNA2 | MAOB 808/4885MAOA 1086/4885IDO1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.